Pulmonx Corp
F:4NI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of
Pulmonx Corp (4NI) under the Base Case is 12.41 EUR per share.
Compared with the current market price of 10.23 EUR, the stock appears
Undervalued by 18% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Pulmonx Does
Pulmonx makes medical devices for people with severe emphysema, a form of COPD that makes it hard to breathe. Its main product is the Zephyr Valve, a tiny implant placed through a bronchoscope to block off badly damaged parts of the lung so healthier areas can work better. The company also sells the Chartis system, which doctors use to test whether a patient is likely to benefit from the valve treatment.
- Headquarters
- United States of America US
- Employees
- 296
- IPO date
- Oct 1, 2020
Balance Sheet
Recent Events
Latest Earnings Call
Pulmonx returned to year-over-year revenue growth in Q3 and said it expects growth to continue as its U.S. sales team ramps and its commercial strategy gains traction.
Open the earnings call- EPS
- −$0.19
- Expected
- −$0.26
- Surprise
- +26.9%
- Stock, next trading day
- +27.3%
Pulmonx insiders are selling less than usual
Past 12 months
Continue 4NI Research
Decided on Pulmonx? Get an email when 4NI reaches the price you’d buy at. Free with an account.
Other Pulmonx listings
What is the Intrinsic Value of one 4NI stock?
The intrinsic value for
Pulmonx Corp (4NI) under the Base Case is 12.41 EUR.
Is 4NI stock undervalued or overvalued?
Compared with the current market price of 10.23 EUR, the stock appears Undervalued by 18% .